<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR27">
 <label>27.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Byrd</surname>
    <given-names>JC</given-names>
   </name>
   <name>
    <surname>Pagel</surname>
    <given-names>JM</given-names>
   </name>
   <name>
    <surname>Awan</surname>
    <given-names>FT</given-names>
   </name>
   <name>
    <surname>Forero</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Flinn</surname>
    <given-names>IW</given-names>
   </name>
   <name>
    <surname>Deauna-Limayo</surname>
    <given-names>DP</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia</article-title>
  <source>Blood</source>
  <year>2014</year>
  <volume>123</volume>
  <fpage>1302</fpage>
  <lpage>1308</lpage>
  <pub-id pub-id-type="doi">10.1182/blood-2013-07-512137</pub-id>
  <?supplied-pmid 24381226?>
  <pub-id pub-id-type="pmid">24381226</pub-id>
 </element-citation>
</ref>
